vimarsana.com

Page 30 - தலை ஆஃப் முதலீட்டாளர் உறவுகள் பெருநிறுவன தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Rollins Financial to Join Focus as a Partner Firm, Expanding Focus Presence in the Southeast

Rollins Financial to Join Focus as a Partner Firm, Expanding Focus Presence in the Southeast
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.

Rollins Financial to Join Focus as a Partner Firm, Expanding Focus Presence in the Southeast

Rollins Financial to Join Focus as a Partner Firm, Expanding Focus Presence in the Southeast
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.

Rollins Financial to Join Focus as a Partner Firm, Expanding Focus Presence in the Southeast

Rollins Financial to Join Focus as a Partner Firm, Expanding Focus Presence in the Southeast
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.

Idorsia Pharmaceuticals Ltd: Idorsia submits NDA for clazosentan to Japanese PMDA

Idorsia Pharmaceuticals Ltd: Idorsia submits NDA for clazosentan to Japanese PMDA Allschwil, Switzerland - March 1, 2021 Idorsia Ltd (SIX: IDIA) today announced the submission of a New Drug Application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for clazosentan, a fast-acting, selective endothelin A (ET A) receptor antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH). The application is supported by replicated results from the Japanese registration program which consisted of two double-blind, randomized, placebo-controlled studies assessing the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause mortality events in adult Japanese patients following aSAH. Patients were randomized to receive continuous infusion of either 10 mg/hr clazosentan or placebo for up to 15 days following the onset of aSAH. The

Investegate |Schaltbau Holding AG Announcements | Schaltbau Holding AG: Conclusion of a pre-placement agreement and intended subscription offer for mandatory convertible bonds

DGAP-Ad-hoc: Schaltbau Holding AG / Key word(s): Financing Schaltbau Holding AG: Conclusion of a pre-placement agreement and intended subscription offer for mandatory convertible bonds 01-March-2021 / 19:42 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Schaltbau Holding AG: Conclusion of a pre-placement agreement and intended subscription offer for mandatory convertible bonds Munich, 1 March 2021 - Today, Schaltbau Holding AG [ISIN DE000A2NBTL2] (hereinafter also Schaltbau or Company ) entered into a pre-placement agreement with the investors of the AiC-Group under the leadership of Luxempart, Active Ownership Group, Shareholder Value Management and Teslin Capital Management (manager of the Midlin and Gerlin funds). Under the terms of this agreement, the investors have undertaken to purchase all mand

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.